Shares of Exact Sciences Corporation (NASDAQ:EXAS) have received an average recommendation of “Buy” from the seventeen research firms that are presently covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $50.28.

Several research firms recently issued reports on EXAS. Robert W. Baird downgraded shares of Exact Sciences Corporation from an “outperform” rating to a “neutral” rating and set a $56.00 price target on the stock. in a research note on Monday, November 13th. Leerink Swann reaffirmed an “outperform” rating and set a $67.00 price target (up previously from $63.00) on shares of Exact Sciences Corporation in a research note on Monday, November 13th. BTIG Research downgraded shares of Exact Sciences Corporation from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 1st. Zacks Investment Research downgraded shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, Jefferies Group LLC lifted their price target on shares of Exact Sciences Corporation to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, October 31st.

Exact Sciences Corporation (EXAS) traded down $0.58 during trading on Monday, reaching $59.17. 745,400 shares of the company traded hands, compared to its average volume of 2,511,738. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $63.60. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01.

Exact Sciences Corporation (NASDAQ:EXAS) last released its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. Exact Sciences Corporation had a negative net margin of 60.71% and a negative return on equity of 30.32%. The firm had revenue of $72.60 million for the quarter, compared to the consensus estimate of $65.03 million. During the same quarter in the previous year, the firm posted ($0.36) EPS. The firm’s quarterly revenue was up 158.4% on a year-over-year basis. equities analysts expect that Exact Sciences Corporation will post -1.12 EPS for the current fiscal year.

In other news, insider Kevin T. Conroy sold 134,057 shares of the business’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total value of $7,976,391.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP D Scott Coward sold 29,115 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the completion of the sale, the senior vice president now directly owns 64,991 shares of the company’s stock, valued at approximately $3,064,975.56. The disclosure for this sale can be found here. Insiders sold a total of 549,235 shares of company stock valued at $28,761,750 in the last three months. Insiders own 4.00% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio boosted its holdings in shares of Exact Sciences Corporation by 69.7% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 122,201 shares of the medical research company’s stock valued at $5,758,000 after buying an additional 50,185 shares during the period. Piedmont Investment Advisors LLC acquired a new position in shares of Exact Sciences Corporation in the 3rd quarter valued at about $514,000. California Public Employees Retirement System boosted its holdings in shares of Exact Sciences Corporation by 2.8% in the 3rd quarter. California Public Employees Retirement System now owns 190,338 shares of the medical research company’s stock valued at $8,969,000 after buying an additional 5,238 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Exact Sciences Corporation by 117.9% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,730 shares of the medical research company’s stock valued at $327,000 after buying an additional 3,642 shares during the period. Finally, AlphaStar Capital Management LLC acquired a new position in shares of Exact Sciences Corporation in the 3rd quarter valued at about $322,000. 86.04% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/11/23/exact-sciences-corporation-exas-receives-50-28-average-pt-from-analysts.html.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.